Stock Scorecard
Stock Summary for GSK Plc (GSK) - $40.86 as of 4/25/2024 7:48:17 AM EST
Total Score
10 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for GSK
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for GSK
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for GSK
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for GSK
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for GSK
Financial Details for GSK
Company Overview |
|
---|---|
Ticker | GSK |
Company Name | GSK Plc |
Country | USA |
Description | GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/1/2024 |
Stock Price History |
|
Last Day Price | 40.86 |
Last Day Price Updated | 4/25/2024 7:48:17 AM EST |
Last Day Volume | 0 |
Average Daily Volume | 2,708,054 |
52-Week High | 43.84 |
52-Week Low | 32.35 |
Last Price to 52 Week Low | 26.31% |
Valuation Measures |
|
Trailing PE | 13.89 |
Industry PE | 100.27 |
Sector PE | 60.54 |
5-Year Average PE | 8.39 |
Free Cash Flow Ratio | 28.38 |
Industry Free Cash Flow Ratio | 12.60 |
Sector Free Cash Flow Ratio | 30.19 |
Current Ratio Most Recent Quarter | 0.88 |
Total Cash Per Share | 1.44 |
Book Value Per Share Most Recent Quarter | 3.29 |
Price to Book Ratio | 4.97 |
Industry Price to Book Ratio | 5.66 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 2.75 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
Total Shares Outstanding | 2,043,030,000 |
Market Capitalization | 83,478,205,800 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | 2/22/2024 |
Last Dividend Amount | 0.36 |
Current Dividend Amount | 0.41 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 1.47 |
Trailing Annual Dividend Yield | 3.59% |
Forward Annual Dividend Rate | 1.26 |
Forward Annual Dividend Yield | 3.09% |
5-Year Dividend Payments Count | 20 |
3-Year Average Dividend Yield | 5.02% |
5-Year Average Dividend Yield | 5.36% |
1-Year Dividend Growth Rate Percentage | -26.00% |
3-Year Dividend Growth Rate Percentage | -28.54% |
5-Year Dividend Growth Rate Percentage | -13.83% |
All-Time Dividend Growth Rate Percentage | 9.85% |
Dividend Payout Ratio | 49.06% |
Income Statement |
|
Quarterly Earnings Growth YOY | -76.60% |
Annual Earnings Growth | 0.14% |
Reported EPS 12 Trailing Months | 2.97 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | 3.87 |
Net Income Twelve Trailing Months | 4,928,000,000 |
Net Income Past Year | 4,928,000,000 |
Net Income Prior Year | 4,921,000,000 |
Quarterly Revenue Growth YOY | 9.20% |
5-Year Revenue Growth | -0.32% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 2,936,000,000 |
Total Cash Past Year | 2,936,000,000 |
Total Cash Prior Year | 3,723,000,000 |
Net Cash Position Most Recent Quarter | -11,218,000,000 |
Net Cash Position Past Year | -11,218,000,000 |
Long Term Debt Past Year | 14,154,000,000 |
Long Term Debt Prior Year | 17,035,000,000 |
Total Debt Most Recent Quarter | 14,154,000,000 |
Equity to Debt Ratio Past Year | 0.49 |
Equity to Debt Ratio Most Recent Quarter | 0.49 |
Total Stockholder Equity Past Year | 13,347,000,000 |
Total Stockholder Equity Prior Year | 10,598,000,000 |
Total Stockholder Equity Most Recent Quarter | 13,347,000,000 |
Options |
|
Put/Call Ratio | 0.10 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.63 |
MACD Signal | -0.44 |
20-Day Bollinger Lower Band | 36.08 |
20-Day Bollinger Middle Band | 40.29 |
20-Day Bollinger Upper Band | 44.50 |
Beta | 0.27 |
RSI | 38.73 |
50-Day SMA | 36.84 |
200-Day SMA | 40.25 |
System |
|
Modified | 4/25/2024 2:00:29 AM EST |